Stressgen gestern + 15,9 % - heute ??? - 500 Beiträge pro Seite
eröffnet am 07.06.01 14:56:03 von
neuester Beitrag 08.08.02 14:49:54 von
neuester Beitrag 08.08.02 14:49:54 von
Beiträge: 38
ID: 417.038
ID: 417.038
Aufrufe heute: 0
Gesamt: 2.041
Gesamt: 2.041
Aktive User: 0
ISIN: US40624Q3020 · WKN: A3D38X · Symbol: HALL
0,6500
USD
-3,68 %
-0,0249 USD
Letzter Kurs 04.05.24 Nasdaq OTC
Werte aus der Branche Finanzdienstleistungen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,3500 | +33,66 | |
| 32,00 | +27,95 | |
| 2,5000 | +25,00 | |
| 0,5800 | +23,40 | |
| 6,1100 | +18,64 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8775 | -14,17 | |
| 1,2600 | -16,00 | |
| 18,445 | -16,65 | |
| 1.138,25 | -16,86 | |
| 0,9150 | -21,79 |
Feedback
Die kanadische Aktie Stressgen Biotechs (WKN 901062) verzeichnete gestern
eine Kurssteigerung von 15,9 %.
Heute sehen wir mindestens die 6,00 Euro!
Preliminary Clinical Data Demonstrate Robust Activity for HspE7
6/6/01
STRESSGEN BIOTECHNOLOGIES CORP ("SSB-T") - Preliminary Clinical Data Demonstrate Robust Activity for HspE7 - in Genital Warts
Stressgen Biotechnologies Corporation announced that new data presented at the American Society of Colon and Rectal Surgeons Annual Meeting, June 2-7, 2001 suggest that HspE7 may be active in treating genital warts caused by the human papillomavirus (HPV). The clinical observations reported retrospectively were made during Stressgen`s Phase II open-label trial in anal dysplasia (AIN) where 14 of the first 22 patients enrolled at one study center also had genital warts. At six months, 13 of 14 patients (93%) responded to HspE7. Of the total patients reported, 10 of 14 (71%) had warts reduced in size 70-95% and 3 of 14 (21%) had complete resolution. These responses are not HPV-16 specific, indicating that HspE7 activity crosses multiple HPV types.
"These data suggest that HspE7 is broadly active in anogenital warts, enhancing its potential as an important new therapeutic for HPV-related diseases," said John R. Neefe, M.D., Vice President of Clinical and Regulatory Affairs of Stressgen. Encouraged by these observations, Stressgen has opened a randomized double-blind, placebo-controlled Phase II trial designed to examine the activity of HspE7 in genital warts. Enrollment in this trial is complete and data from this trial should be available for analysis in the fourth quarter of 2001.
Genital warts are caused by certain types of HPV, one of the most common sexually transmitted diseases in the world infecting 24 million people in the U.S. alone. There are 5.5 million new cases of genital HPV infection diagnosed per year in the U.S., of which over one million represent new cases of genital warts. Existing treatments for genital warts use ablative methods, involving surgery or the application of topical agents to the surface of each wart. The majority of patients, however, will experience recurrent episodes within three to six months. In addition to genital warts, HPV is responsible for a variety of precancerous and cancerous conditions. HPV is also responsible for a serious HPV-related disease known as recurrent respiratory papillomatosis (RRP), which is caused by the same types that cause genital warts.
"The medical community is becoming increasingly aware of the seriousness of HPV-related diseases such as genital warts and precancerous lesions. Treatment recommendations are evolving, however, many patients require some form of surgical ablative treatment. With the high recurrence of genital warts, these procedures are painful and can leave the patient debilitated over many weeks to months of repeated treatments. New therapies are badly needed, and the possibility of an immune-based therapy is very exciting because it has the potential to avoid surgery, improve quality of life and hopefully decrease recurrence. These HspE7 clinical data appear to be very promising. I look forward to further clinical results," said Stephen E. Goldstone, M.D. Dr. Goldstone, a leading AIN specialist, is a Fellow of the American College of Surgeons. He is on the teaching faculty of The Mount Sinai School of Medicine and has a surgical practice in New York City.
Results presented today by Dr. Goldstone were in the form of a retrospective chart review from patients evaluated by physical examination at baseline and six months as to the percentage reduction in wart size. The reduction in wart size in the 13 responders markedly diminished the procedure that would be necessary for complete ablation. Of the 14 patients with genital warts, one patient did not respond to HspE7. In the majority, the warts improved substantially but did not disappear totally within six months. No serious adverse events in the patients reported were related to HspE7.
HspE7, a recombinant fusion product created with Stressgen`s proprietary Hsp fusion technology, is composed of heat shock protein 65 (Hsp65) from Mycobacterium bovis BCG and the protein E7. As a member of the family of stress proteins, Hsp65 is known to elicit a powerful immune response. The E7 protein is derived from HPV and is involved in the malignant transformation of epithelial cells. E7 is a tumor-specific antigen and represents a precise target for the immune system to attack abnormal cells.
About Stressgen
Stressgen is a public biopharmaceutical company focused on the development and commercialization of innovative stress protein-based immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. In addition to targeting HspE7 in HPV-related diseases, the Company has also initiated research studies to evaluate its heat shock protein technology in the treatment of viral diseases such as hepatitis. Stressgen is also an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology, which are used by scientists worldwide.
About Conference Call
Stressgen`s conference call will be held on June 7, 2001 at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). The dial in number to access the call is 888-489-9485 in North America. A replay of this call will be available from June 7 at 8:00 a.m. Pacific Time through June 14, 2001. The playback number is: 800-558-5253, reservation No. 19040166. The Company will retain information about accessing the call on its website at www.stressgen.com through the playback period.
This news release contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding the efficacy of HspE7 in HPV-related diseases, the timing and potential results of the Company`s clinical trials and the Company`s ability to develop therapeutics. Such statements are only predictions. Factors that may cause the ultimate results or our performance to be materially different from those implied by such statements include risks that there will be delays in conducting clinical trials, that products that appeared promising in early research do not demonstrate safety or efficacy in larger-scale clinical trials, and that it will be difficult to progress from research to commercialization. These factors and others are more fully discussed in our Quarterly Report on Form 10-Q and other filings with the U.S. Securities and Exchange Commission and Canadian regulatory authorities. The Company does not assume any obligation to update or alter the contents of this news release. TEL: (858) 812-5616 Donna Slade, Director, Investor Relations FAX: (858) 812-5613 E-mail: dslade@stressgen.com TEL: (250) 744-2811 Jennifer Matterson, Communications Coordinator FAX: (250) 744-3331 E-mail: jmatterson@stressgen.com
eine Kurssteigerung von 15,9 %.
Heute sehen wir mindestens die 6,00 Euro!
Preliminary Clinical Data Demonstrate Robust Activity for HspE7
6/6/01
STRESSGEN BIOTECHNOLOGIES CORP ("SSB-T") - Preliminary Clinical Data Demonstrate Robust Activity for HspE7 - in Genital Warts
Stressgen Biotechnologies Corporation announced that new data presented at the American Society of Colon and Rectal Surgeons Annual Meeting, June 2-7, 2001 suggest that HspE7 may be active in treating genital warts caused by the human papillomavirus (HPV). The clinical observations reported retrospectively were made during Stressgen`s Phase II open-label trial in anal dysplasia (AIN) where 14 of the first 22 patients enrolled at one study center also had genital warts. At six months, 13 of 14 patients (93%) responded to HspE7. Of the total patients reported, 10 of 14 (71%) had warts reduced in size 70-95% and 3 of 14 (21%) had complete resolution. These responses are not HPV-16 specific, indicating that HspE7 activity crosses multiple HPV types.
"These data suggest that HspE7 is broadly active in anogenital warts, enhancing its potential as an important new therapeutic for HPV-related diseases," said John R. Neefe, M.D., Vice President of Clinical and Regulatory Affairs of Stressgen. Encouraged by these observations, Stressgen has opened a randomized double-blind, placebo-controlled Phase II trial designed to examine the activity of HspE7 in genital warts. Enrollment in this trial is complete and data from this trial should be available for analysis in the fourth quarter of 2001.
Genital warts are caused by certain types of HPV, one of the most common sexually transmitted diseases in the world infecting 24 million people in the U.S. alone. There are 5.5 million new cases of genital HPV infection diagnosed per year in the U.S., of which over one million represent new cases of genital warts. Existing treatments for genital warts use ablative methods, involving surgery or the application of topical agents to the surface of each wart. The majority of patients, however, will experience recurrent episodes within three to six months. In addition to genital warts, HPV is responsible for a variety of precancerous and cancerous conditions. HPV is also responsible for a serious HPV-related disease known as recurrent respiratory papillomatosis (RRP), which is caused by the same types that cause genital warts.
"The medical community is becoming increasingly aware of the seriousness of HPV-related diseases such as genital warts and precancerous lesions. Treatment recommendations are evolving, however, many patients require some form of surgical ablative treatment. With the high recurrence of genital warts, these procedures are painful and can leave the patient debilitated over many weeks to months of repeated treatments. New therapies are badly needed, and the possibility of an immune-based therapy is very exciting because it has the potential to avoid surgery, improve quality of life and hopefully decrease recurrence. These HspE7 clinical data appear to be very promising. I look forward to further clinical results," said Stephen E. Goldstone, M.D. Dr. Goldstone, a leading AIN specialist, is a Fellow of the American College of Surgeons. He is on the teaching faculty of The Mount Sinai School of Medicine and has a surgical practice in New York City.
Results presented today by Dr. Goldstone were in the form of a retrospective chart review from patients evaluated by physical examination at baseline and six months as to the percentage reduction in wart size. The reduction in wart size in the 13 responders markedly diminished the procedure that would be necessary for complete ablation. Of the 14 patients with genital warts, one patient did not respond to HspE7. In the majority, the warts improved substantially but did not disappear totally within six months. No serious adverse events in the patients reported were related to HspE7.
HspE7, a recombinant fusion product created with Stressgen`s proprietary Hsp fusion technology, is composed of heat shock protein 65 (Hsp65) from Mycobacterium bovis BCG and the protein E7. As a member of the family of stress proteins, Hsp65 is known to elicit a powerful immune response. The E7 protein is derived from HPV and is involved in the malignant transformation of epithelial cells. E7 is a tumor-specific antigen and represents a precise target for the immune system to attack abnormal cells.
About Stressgen
Stressgen is a public biopharmaceutical company focused on the development and commercialization of innovative stress protein-based immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. In addition to targeting HspE7 in HPV-related diseases, the Company has also initiated research studies to evaluate its heat shock protein technology in the treatment of viral diseases such as hepatitis. Stressgen is also an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology, which are used by scientists worldwide.
About Conference Call
Stressgen`s conference call will be held on June 7, 2001 at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). The dial in number to access the call is 888-489-9485 in North America. A replay of this call will be available from June 7 at 8:00 a.m. Pacific Time through June 14, 2001. The playback number is: 800-558-5253, reservation No. 19040166. The Company will retain information about accessing the call on its website at www.stressgen.com through the playback period.
This news release contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding the efficacy of HspE7 in HPV-related diseases, the timing and potential results of the Company`s clinical trials and the Company`s ability to develop therapeutics. Such statements are only predictions. Factors that may cause the ultimate results or our performance to be materially different from those implied by such statements include risks that there will be delays in conducting clinical trials, that products that appeared promising in early research do not demonstrate safety or efficacy in larger-scale clinical trials, and that it will be difficult to progress from research to commercialization. These factors and others are more fully discussed in our Quarterly Report on Form 10-Q and other filings with the U.S. Securities and Exchange Commission and Canadian regulatory authorities. The Company does not assume any obligation to update or alter the contents of this news release. TEL: (858) 812-5616 Donna Slade, Director, Investor Relations FAX: (858) 812-5613 E-mail: dslade@stressgen.com TEL: (250) 744-2811 Jennifer Matterson, Communications Coordinator FAX: (250) 744-3331 E-mail: jmatterson@stressgen.com
hab ich auch gedacht, dass es aufwärts geht. bin seit genau 1 jahr dabei (kk 3.6 Euro) und hab mich beim Anstieg auf über 7 geärgert nur wenige gekauft zu haben. also gestern nochmal nachgelegt zu 5 euro. bin mal gespannt ob es heute weitergeht oder ob die luft schon wieder raus ist.
grüße
grüße
Entlich gehts wieder los hier auf dem Board!!
Hab mich jetzt 1 Jahr rausgehalten und hab nur noch in Canada in den Boards mitgeschrieben!!
Also ich empfehle allen das stockhouse-Board - Topaktuell und lauter kompetente Leute!!
Adresse: www.stockhouse.com dann stressgen eingeben und schon seit ihr in unserer Zukunftswelt!!
Grüsse an alle Stressgener der ersten Stunde - ich hoffe unsere "stressige" Aktie ist bald ganz erholsam....
Grüße
akmad
P.s. hier noch ein Tip: Aeterna Labs. auch eine kanadische Biotechfirma - ist kurz (ca. 1 Jahr) davor ihr Hauptprodukt Neovestat auf den Markt zu bringen. Kürzel bei yahoo: ael.to
Hab mich jetzt 1 Jahr rausgehalten und hab nur noch in Canada in den Boards mitgeschrieben!!
Also ich empfehle allen das stockhouse-Board - Topaktuell und lauter kompetente Leute!!
Adresse: www.stockhouse.com dann stressgen eingeben und schon seit ihr in unserer Zukunftswelt!!
Grüsse an alle Stressgener der ersten Stunde - ich hoffe unsere "stressige" Aktie ist bald ganz erholsam....
Grüße
akmad
P.s. hier noch ein Tip: Aeterna Labs. auch eine kanadische Biotechfirma - ist kurz (ca. 1 Jahr) davor ihr Hauptprodukt Neovestat auf den Markt zu bringen. Kürzel bei yahoo: ael.to
und heute -16%
boriz
boriz
und heute +11,5%.
morgen Konferenz.
würd mich wundern, wenns super spannende neuigkeiten gibt. dann wäre der kurs in ca. etwas signifikannter nach oben gegangen bzw. mit höheren umsätzen...
morgen Konferenz.
würd mich wundern, wenns super spannende neuigkeiten gibt. dann wäre der kurs in ca. etwas signifikannter nach oben gegangen bzw. mit höheren umsätzen...
Trading Spotlight
Ja und was wurde nun bei der Konferenz bekanntgegeben ??
So wie der Kurs sich verhalten hat, wohl nichts neues ??
So wie der Kurs sich verhalten hat, wohl nichts neues ??
Oder vielleicht doch ??
Wenn der Kurs sich weiter so erholt sind wir bald wieder bei 6 E, und dann geht es wieder erst richtig los.
Wenn der Kurs sich weiter so erholt sind wir bald wieder bei 6 E, und dann geht es wieder erst richtig los.
naja, die Konferenz damals hatte wohl nix gutes an sich, danach gings erst mal bergab. mittlerweile tägliche kleine kurssteigerungen. dabei war die meldung vom 19.11. nun auch nicht so umwerfend. aber zeigt, dass stressgen immer noch aktiv ist (den eindruck hatte ich mal ne zeitlang verloren...)
habs damals leider versäumt, bei 7Euro auszusteigen (kk 3.6), hab stattdessen im juni bei 5 nochmal nachgelegt, seit dem gings nur bergab.
weiterhin viel erfolg mit Stressgen!
habs damals leider versäumt, bei 7Euro auszusteigen (kk 3.6), hab stattdessen im juni bei 5 nochmal nachgelegt, seit dem gings nur bergab.
weiterhin viel erfolg mit Stressgen!
Meldung v. 19.11. ????
Die habe ich verpaßt, wo kann man sie nachlesen ??
Die habe ich verpaßt, wo kann man sie nachlesen ??
findest Du unter
finance.yahoo.com
Monday November 19, 7:59 am Eastern Time
Press Release
SOURCE: Stressgen Biotechnologies Corp.
Stressgen initiates Phase II recurrent respiratory papillomatosis trial in children
The Company is Evaluating the Potential of HspE7 to Treat Genital Warts of the Upper Airways
VICTORIA, BC, Nov. 19 /CNW/ - Stressgen Biotechnologies Corporation (TSE: SSB - news) announced today that it has initiated its pilot Phase II open label trial in pediatric patients suffering from a human papillomavirus (HPV)- related disease called recurrent respiratory papillomatosis (RRP). In the U.S., there are about 2,000 new cases each year of pediatric respiratory papillomatosis. The Company was granted orphan drug status for HspE7, a novel immunotherapeutic, from the United States Food and Drug Administration (FDA) in March of this year.
The trial will involve approximately 27 pediatric patients that currently require frequent surgery, and will be conducted in multiple centers in the U.S. The dose will be 500 mcg administered three times at monthly intervals. The endpoint for the trial will be an increased interval between clinically required surgeries. Data from this trial could be available as early as 2002.
"Currently the only treatment available for RRP is surgery," said John R. Neefe, M.D., Vice President, Clinical Research and Regulatory Affairs for Stressgen Biotechnologies. "There are no approved drugs or immunotherapies. The average pediatric patient has about five surgeries per year and some children tragically have hundreds of procedures in their lifetimes."
"Despite the best that current medicine has to offer, the papillomas recur relentlessly and the condition of the disease can be grueling and prolonged," said Daniel L. Korpolinski, President and Chief Executive Officer of Stressgen Biotechnologies. "There is a tremendous need for new treatment options in this population. Because HspE7 has demonstrated activity in other conditions caused by the HPV subtypes 6 and 11 associated with RRP, it is very important to test HspE7 in this disease. Considering HspE7`s orphan drug status in this indication, RRP may provide the shortest route to market for Stressgen."
Scientists believe HspE7 works by stimulating the cell-mediated portion of the immune system. Currently studies are underway in the treatment of anal and cervical dysplasia and genital warts. In a preliminary report in anal dysplasia patients, over 70% of these individuals converted from high grade to low grade lesions within six months of treatment. In a retrospective study of genital warts, over 90% of the patients showed complete or partial response at 24 weeks. RRP is caused by the same HPV subtypes 6 and 11 that are the most common cause of genital warts.
About Stressgen Biotechnologies
Stressgen is a public biopharmaceutical company focused on the development and commercialization of innovative stress protein-based immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. In addition to targeting HspE7 in HPV-related diseases, the Company also has a program to evaluate stress protein fusions in hepatitis B and has initiated research studies to evaluate its heat shock protein technology in the treatment of several other indications. Stressgen is also an internationally recognized supplier of research products used by scientists worldwide for the study of cellular stress, apoptosis, oxidative stress and neurobiology.
HspE7 is a novel immunotherapeutic for the treatment of diseases caused by the human papillomavirus ("HPV"), one of the most common sexually transmitted diseases, estimated to infect approximately 30 to 50 percent of the sexually active population. There are 5.5 million new cases of genital HPV infection diagnosed per year in the U.S. alone, of which over 1 million represent cases of genital warts. In addition to warts, genital HPV infection can cause cervical cancer and a variety of precancerous conditions, including anal and cervical dysplasia.
This news release contains certain forward-looking statements that involve risks and uncertainties, including statements regarding the timing of the Company`s clinical trials and its ability to bring therapeutics to market. Factors that may cause the ultimate results or our performance to be materially different from those implied by such statements include risks that products that appeared promising in early research do not demonstrate safety or efficacy in larger-scale clinical trials, that the company will not obtain approval to market its products, and that it will be difficult to progress from research to commercialization. These factors and others are more fully discussed in our quarterly reports on Form 10-Q and other filings with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission.
finance.yahoo.com
Monday November 19, 7:59 am Eastern Time
Press Release
SOURCE: Stressgen Biotechnologies Corp.
Stressgen initiates Phase II recurrent respiratory papillomatosis trial in children
The Company is Evaluating the Potential of HspE7 to Treat Genital Warts of the Upper Airways
VICTORIA, BC, Nov. 19 /CNW/ - Stressgen Biotechnologies Corporation (TSE: SSB - news) announced today that it has initiated its pilot Phase II open label trial in pediatric patients suffering from a human papillomavirus (HPV)- related disease called recurrent respiratory papillomatosis (RRP). In the U.S., there are about 2,000 new cases each year of pediatric respiratory papillomatosis. The Company was granted orphan drug status for HspE7, a novel immunotherapeutic, from the United States Food and Drug Administration (FDA) in March of this year.
The trial will involve approximately 27 pediatric patients that currently require frequent surgery, and will be conducted in multiple centers in the U.S. The dose will be 500 mcg administered three times at monthly intervals. The endpoint for the trial will be an increased interval between clinically required surgeries. Data from this trial could be available as early as 2002.
"Currently the only treatment available for RRP is surgery," said John R. Neefe, M.D., Vice President, Clinical Research and Regulatory Affairs for Stressgen Biotechnologies. "There are no approved drugs or immunotherapies. The average pediatric patient has about five surgeries per year and some children tragically have hundreds of procedures in their lifetimes."
"Despite the best that current medicine has to offer, the papillomas recur relentlessly and the condition of the disease can be grueling and prolonged," said Daniel L. Korpolinski, President and Chief Executive Officer of Stressgen Biotechnologies. "There is a tremendous need for new treatment options in this population. Because HspE7 has demonstrated activity in other conditions caused by the HPV subtypes 6 and 11 associated with RRP, it is very important to test HspE7 in this disease. Considering HspE7`s orphan drug status in this indication, RRP may provide the shortest route to market for Stressgen."
Scientists believe HspE7 works by stimulating the cell-mediated portion of the immune system. Currently studies are underway in the treatment of anal and cervical dysplasia and genital warts. In a preliminary report in anal dysplasia patients, over 70% of these individuals converted from high grade to low grade lesions within six months of treatment. In a retrospective study of genital warts, over 90% of the patients showed complete or partial response at 24 weeks. RRP is caused by the same HPV subtypes 6 and 11 that are the most common cause of genital warts.
About Stressgen Biotechnologies
Stressgen is a public biopharmaceutical company focused on the development and commercialization of innovative stress protein-based immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. In addition to targeting HspE7 in HPV-related diseases, the Company also has a program to evaluate stress protein fusions in hepatitis B and has initiated research studies to evaluate its heat shock protein technology in the treatment of several other indications. Stressgen is also an internationally recognized supplier of research products used by scientists worldwide for the study of cellular stress, apoptosis, oxidative stress and neurobiology.
HspE7 is a novel immunotherapeutic for the treatment of diseases caused by the human papillomavirus ("HPV"), one of the most common sexually transmitted diseases, estimated to infect approximately 30 to 50 percent of the sexually active population. There are 5.5 million new cases of genital HPV infection diagnosed per year in the U.S. alone, of which over 1 million represent cases of genital warts. In addition to warts, genital HPV infection can cause cervical cancer and a variety of precancerous conditions, including anal and cervical dysplasia.
This news release contains certain forward-looking statements that involve risks and uncertainties, including statements regarding the timing of the Company`s clinical trials and its ability to bring therapeutics to market. Factors that may cause the ultimate results or our performance to be materially different from those implied by such statements include risks that products that appeared promising in early research do not demonstrate safety or efficacy in larger-scale clinical trials, that the company will not obtain approval to market its products, and that it will be difficult to progress from research to commercialization. These factors and others are more fully discussed in our quarterly reports on Form 10-Q and other filings with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission.
dankeschön, liest sich ja ganz gut.
tja, und schon die nächste meldung:
Tuesday November 27, 7:59 am Eastern Time
Press Release
SOURCE: Stressgen Biotechnologies Corp.
Stressgen conference call notification - New Phase II Data for HspE7
Thursday, November 29, 2001 - 8:30 a.m. ET; 5:30 a.m. PT
VICTORIA, BC, Nov. 27 /CNW/ - Stressgen Biotechnologies Corporation (TSE:SSB - news) announced today that it will host a conference call on Thursday, November 29, 2001 to discuss the latest results compiled from six data sets from five key Phase II clinical trials involving its lead "fusion" product candidate, HspE7, a novel immunotherapeutic for the treatment of diseases caused by the human papillomavirus (HPV).
About Conference Call
Und Irgendwie scheint das nicht so gut anzukommen, kurs ist 3,8% im minus in CA.
Tuesday November 27, 7:59 am Eastern Time
Press Release
SOURCE: Stressgen Biotechnologies Corp.
Stressgen conference call notification - New Phase II Data for HspE7
Thursday, November 29, 2001 - 8:30 a.m. ET; 5:30 a.m. PT
VICTORIA, BC, Nov. 27 /CNW/ - Stressgen Biotechnologies Corporation (TSE:SSB - news) announced today that it will host a conference call on Thursday, November 29, 2001 to discuss the latest results compiled from six data sets from five key Phase II clinical trials involving its lead "fusion" product candidate, HspE7, a novel immunotherapeutic for the treatment of diseases caused by the human papillomavirus (HPV).
About Conference Call
Und Irgendwie scheint das nicht so gut anzukommen, kurs ist 3,8% im minus in CA.
uups, schon längst gedreht:
4.8 ca$
also ca.
3.41 Euro
kurs in FSE: 3.25 Euro
4.8 ca$
also ca.
3.41 Euro
kurs in FSE: 3.25 Euro
+13,33% aktuell bei rd. 428.000 Stück umsatz (quelle http://finance.yahoo.com/q?s=SSB.TO&d=t)
solch hoher umsatz war in usa/canada,toronto lange nicht mehr.
Friday January 4, 7:59 am Eastern Time
Press Release
SOURCE: Stressgen Biotechnologies Corp.
Stressgen announces issuance of U.S. patent solidifying its heat shock protein-based technology platform
Fusion Patent Relates to Heat Shock Proteins and Methods of Modulating a Patient`s Immune Response to Treat Diseases
SAN DIEGO, CA, Jan. 4 /CNW/ - Stressgen Biotechnologies Corporation (TSE:SSB - news) announced today that the U.S. Patent and Trademark Office had issued Patent Number 6,335,183, for which the Company has an exclusive worldwide license from the Whitehead Institute for Biomedical Research. The patent grants exclusivity for the method of inducing or enhancing an immune response in a patient by administering a pharmaceutical composition comprising a "fusion protein," a stress protein joined to a viral, cancer or HIV antigen, administered for the purpose of generating an antigen-specific immune response.
"The pre-GATT 17-year exclusivity of this patent will help ensure that our technology for developing heat shock protein fusions to treat viral diseases and cancers will remain proprietary. This is just the first of several patents on our platform technology that we believe will issue during 2002," said Daniel L. Korpolinski, President and Chief Executive Officer of Stressgen Biotechnologies Corporation. "Stressgen and any potential partner should be able to capitalize upon patent exclusivity through 2019 in marketing our fusion candidate for the treatment of human papillomavirus (HPV), which is currently in phase III clinical trials, our fusion candidate for hepatitis B virus, which is currently in early preclinical development, and our fusion candidates for additional diseases including herpes simplex virus and HIV."
"The goal of every biotechnology company is to have the exclusive right to market a compound such as our heat shock protein fusion candidate, HspE7. The recently announced clinical data for HspE7 suggest the immunotherapeutic will be a broad spectrum treatment for HPV-related genital warts and dysplasias with outstanding safety, efficacy and durability of treatment effect," said John R. Neefe, M.D., Vice President of Clinical Research and Regulatory Affairs for Stressgen.
"The need for more effective therapies for infectious diseases and cancers has prompted researchers to explore how our own immune system`s powerful capabilities can be harnessed to fight the major diseases of mankind," said Richard A. Young, Ph.D., Member, Whitehead Institute for Biomedical Research and professor of Biology at the Massachusetts Institute of Technology. "I am excited that the discovery of heat shock proteins and fusions as powerful stimulants of the immune system have evolved to opportunities for new innovative therapeutic interventions."
About Stressgen Biotechnologies
Stressgen is a public biopharmaceutical company focused on the development and commercialization of innovative stress protein-based `fusion` immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. In addition to developing HspE7 for HPV-related diseases, the Company also has a program to evaluate
solch hoher umsatz war in usa/canada,toronto lange nicht mehr.
Friday January 4, 7:59 am Eastern Time
Press Release
SOURCE: Stressgen Biotechnologies Corp.
Stressgen announces issuance of U.S. patent solidifying its heat shock protein-based technology platform
Fusion Patent Relates to Heat Shock Proteins and Methods of Modulating a Patient`s Immune Response to Treat Diseases
SAN DIEGO, CA, Jan. 4 /CNW/ - Stressgen Biotechnologies Corporation (TSE:SSB - news) announced today that the U.S. Patent and Trademark Office had issued Patent Number 6,335,183, for which the Company has an exclusive worldwide license from the Whitehead Institute for Biomedical Research. The patent grants exclusivity for the method of inducing or enhancing an immune response in a patient by administering a pharmaceutical composition comprising a "fusion protein," a stress protein joined to a viral, cancer or HIV antigen, administered for the purpose of generating an antigen-specific immune response.
"The pre-GATT 17-year exclusivity of this patent will help ensure that our technology for developing heat shock protein fusions to treat viral diseases and cancers will remain proprietary. This is just the first of several patents on our platform technology that we believe will issue during 2002," said Daniel L. Korpolinski, President and Chief Executive Officer of Stressgen Biotechnologies Corporation. "Stressgen and any potential partner should be able to capitalize upon patent exclusivity through 2019 in marketing our fusion candidate for the treatment of human papillomavirus (HPV), which is currently in phase III clinical trials, our fusion candidate for hepatitis B virus, which is currently in early preclinical development, and our fusion candidates for additional diseases including herpes simplex virus and HIV."
"The goal of every biotechnology company is to have the exclusive right to market a compound such as our heat shock protein fusion candidate, HspE7. The recently announced clinical data for HspE7 suggest the immunotherapeutic will be a broad spectrum treatment for HPV-related genital warts and dysplasias with outstanding safety, efficacy and durability of treatment effect," said John R. Neefe, M.D., Vice President of Clinical Research and Regulatory Affairs for Stressgen.
"The need for more effective therapies for infectious diseases and cancers has prompted researchers to explore how our own immune system`s powerful capabilities can be harnessed to fight the major diseases of mankind," said Richard A. Young, Ph.D., Member, Whitehead Institute for Biomedical Research and professor of Biology at the Massachusetts Institute of Technology. "I am excited that the discovery of heat shock proteins and fusions as powerful stimulants of the immune system have evolved to opportunities for new innovative therapeutic interventions."
About Stressgen Biotechnologies
Stressgen is a public biopharmaceutical company focused on the development and commercialization of innovative stress protein-based `fusion` immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. In addition to developing HspE7 for HPV-related diseases, the Company also has a program to evaluate
hört sich so an, als ob unsere geduld belohnt wird....
Stressgen shares rise on news of patent approval
TORONTO, Jan 4 (Reuters) - Stressgen Biotechnologies Corp. (Toronto:SSB.TO - news) said on Friday it was granted a U.S. patent giving the drug developer exclusive rights for its method of treating viral diseases and cancer by triggering or boosting an immune response in patients.
ADVERTISEMENT
The company`s stock rose 62 Canadian cents, or 13.7 percent, to C$5.12 on the Toronto Stock Exchange, the highest it has traded in five months.
``With a reasonably broad U.S. patent in place, they have definitely delivered on one of the major milestones needed to move this company ahead,`` said Brian Bapty, an analyst with Raymond James Ltd, adding that the company still needs to find a corporate partnership, a move expected this year.
``They have delivered on the first of the two big issues and from a top-down perspective we find the company attractive.``
Stressgen said in a statement the patent will help ensure its technology for developing heat shock protein fusions to treat viral diseases and cancers remains proprietary.
The company also said any potential partner should be able to capitalize on patent exclusivity through marketing its fusion candidates for the treatments of human papillomavirus, hepatitis B and other diseases, including herpes simplex virus and HIV.
Bapty said he likes the way the company is shaping up and maintained a ``strong buy`` rating on the stock.
($1 equals $1.60 Canadian)
Stressgen shares rise on news of patent approval
TORONTO, Jan 4 (Reuters) - Stressgen Biotechnologies Corp. (Toronto:SSB.TO - news) said on Friday it was granted a U.S. patent giving the drug developer exclusive rights for its method of treating viral diseases and cancer by triggering or boosting an immune response in patients.
ADVERTISEMENT
The company`s stock rose 62 Canadian cents, or 13.7 percent, to C$5.12 on the Toronto Stock Exchange, the highest it has traded in five months.
``With a reasonably broad U.S. patent in place, they have definitely delivered on one of the major milestones needed to move this company ahead,`` said Brian Bapty, an analyst with Raymond James Ltd, adding that the company still needs to find a corporate partnership, a move expected this year.
``They have delivered on the first of the two big issues and from a top-down perspective we find the company attractive.``
Stressgen said in a statement the patent will help ensure its technology for developing heat shock protein fusions to treat viral diseases and cancers remains proprietary.
The company also said any potential partner should be able to capitalize on patent exclusivity through marketing its fusion candidates for the treatments of human papillomavirus, hepatitis B and other diseases, including herpes simplex virus and HIV.
Bapty said he likes the way the company is shaping up and maintained a ``strong buy`` rating on the stock.
($1 equals $1.60 Canadian)
wäre nicht schlecht wenn Stressgen mal steigen würde, hab sie mal bei 10,50 gekauft.........
uups, 10,5euro oder ca$ ? jedenfalls sind solche kurse leider lange her?
aber so wie die nachrichten sich anhören und unter berücksichtigung des hohen handelsvolumens (wir sind schon wieder über 400.000, am freitag warens 600.000, üblich sonst so max 30.000) sind wir zumindest wieder auf dem weg richtung 4,5-5
drücke uns die daumen...
grüße
toller
aber so wie die nachrichten sich anhören und unter berücksichtigung des hohen handelsvolumens (wir sind schon wieder über 400.000, am freitag warens 600.000, üblich sonst so max 30.000) sind wir zumindest wieder auf dem weg richtung 4,5-5
drücke uns die daumen...
grüße
toller
10.5€ waren das und zwar hab ich die im März 2000 gekauft, immer wieder mal überlegt ob ich nachkaufen soll.
Daumen drücken werd ich jedenfalls auch!!
Daumen drücken werd ich jedenfalls auch!!
naja, da hast du ja genau die spitze eines spitzentages erwischt...aber tröste Dich, von solchen aktien schlummert bei mir auch einiges (z.B. Steag, KK 44Euro oder senator kk 22 euro).
ich hab meine ersten stressgen für 3.5 erstanden und bei 5 nochmal nachgelegt (leider ne doppelt so große position wie die erste charge), so dass ich jetzt auch noch im minus bin.
also, hoffentlich hat sich für uns das durchstehen der dursttrecke gelohnt.
grüße
toller
ich hab meine ersten stressgen für 3.5 erstanden und bei 5 nochmal nachgelegt (leider ne doppelt so große position wie die erste charge), so dass ich jetzt auch noch im minus bin.
also, hoffentlich hat sich für uns das durchstehen der dursttrecke gelohnt.
grüße
toller
es wird jedenfalls wieder stark gehandelt mit stressgen, dass freut mich. manchmal hatte ich den eindruck, dass die aktie sogar in Canada bzw. usa eingschlafen ist. bei uns liegen die umsätze ja eh immer äusserts niedrig.
scheint, dass die händler sich erst mal ausgetobt haben bei stressgen. heute "nur" rund 180.000 stück gehandelt.
vielleicht nur ne verschnaufpause. hoffentlich fallen die üblichen gewinnmitnahmen nach dem anstieg nicht so nachhaltig aus.
vielleicht nur ne verschnaufpause. hoffentlich fallen die üblichen gewinnmitnahmen nach dem anstieg nicht so nachhaltig aus.
Hab heute mal bei Stockhouse.com geschaut, ganz schön was los aufm Board, anders wie hier. Stressgen ist ja immer noch bei Phase 2 wenn ich es richtig verstanden hab, oder?
konnte das nicht rauskopieren, aber unter dem link
http://www.stressgen.com/product/pipeline.htm
findest Du informationen zur Produktpipeline von Stressgen.
für das Jahr 2001 geben sie auch ne übersicht über die ergebnisse, da taucht auch etwas von Ergebnissen des HspE7 bei Anal Intraepithelial Neoplasia (AIN) in Phase III auf.
Jan. 9
Stressgen initiated Phase II trial in genital warts
Mar. 29
Stressgen receives Orphan Drug status for recurrent respiratory papillomatosis (RRP)
Apr. 10
Stressgen completes genital warts program ahead of schedule due to early completion of patient enrollment
Apr. 24
Stressgen presents new data with HspE7; data confirm earlier findings that 73% of patients downgrade from high to low dysplasia
June 6
Stressgen announces preliminary clinical data that demonstrates robust activity for HspE7 in genital warts
Aug. 1
Stressgen announces early enrollment for HspE7 Phase III AIN trial
Sept. 4
Announced Positive HspE7 Data that 71% of High Grade Anal Dysplasia Patients Treated May Avoid Surgery
Nov. 19
Initiated HspE7 Phase II Recurrent Respiratory Papillomatosis (RRP) Trial in Children
http://www.stressgen.com/product/pipeline.htm
findest Du informationen zur Produktpipeline von Stressgen.
für das Jahr 2001 geben sie auch ne übersicht über die ergebnisse, da taucht auch etwas von Ergebnissen des HspE7 bei Anal Intraepithelial Neoplasia (AIN) in Phase III auf.
Jan. 9
Stressgen initiated Phase II trial in genital warts
Mar. 29
Stressgen receives Orphan Drug status for recurrent respiratory papillomatosis (RRP)
Apr. 10
Stressgen completes genital warts program ahead of schedule due to early completion of patient enrollment
Apr. 24
Stressgen presents new data with HspE7; data confirm earlier findings that 73% of patients downgrade from high to low dysplasia
June 6
Stressgen announces preliminary clinical data that demonstrates robust activity for HspE7 in genital warts
Aug. 1
Stressgen announces early enrollment for HspE7 Phase III AIN trial
Sept. 4
Announced Positive HspE7 Data that 71% of High Grade Anal Dysplasia Patients Treated May Avoid Surgery
Nov. 19
Initiated HspE7 Phase II Recurrent Respiratory Papillomatosis (RRP) Trial in Children
So, jetzt bin ich auch wieder da.
Nach langem Hin und Her bin ich bei einem Durchschnittskurs von 5,3 E gelandet.
Hatte leztes Jahr mal über 100 % gehabt, diese in einen Schrottwert (jetzt Pleite!!) investiert und dann wieder ein - und nachgekauft.
Diesmal bleibe ich einfach drin und warte ab, egal wie lange!
Jetzt aber meine Frage:
Weiß jemand welche Fonds in Stressgen investieren und vielleicht auch noch seit wann ???
Nach langem Hin und Her bin ich bei einem Durchschnittskurs von 5,3 E gelandet.
Hatte leztes Jahr mal über 100 % gehabt, diese in einen Schrottwert (jetzt Pleite!!) investiert und dann wieder ein - und nachgekauft.
Diesmal bleibe ich einfach drin und warte ab, egal wie lange!
Jetzt aber meine Frage:
Weiß jemand welche Fonds in Stressgen investieren und vielleicht auch noch seit wann ???
Stressgen im Strudel von ImClone oder wie siehst Du das,toller??? Irgendein Anal-yst hat mal gesagt `02 sei das Jahr der Biotechs, da bin ich ja mal gespannt-Danke für Dein letztes Posting!
könnte gut sein, das mit dem abwärtssog. denke aber auch, dass da einige gewinnmitnahmen dabei sind. schließlich war der anstieg ganz nett in den tagen davor.
Tuesday January 15, 9:23 am Eastern Time
Press Release
SOURCE: Stressgen Biotechnologies Corp.
New U.S. composition patent firmly solidifies Stressgen`s position in heat shock protein fusion technology
Stressgen Broadens Heat Shock Protein Patent Estate With Issuance of Second U.S. Patent
SAN DIEGO, CA, Jan. 15 /CNW/ - Stressgen Biotechnologies Corporation (TSE:SSB - news) announced today that the U.S. Patent and Trademark Office has issued Patent Number 6,338,952, for which the Company has an exclusive worldwide license from the Whitehead Institute for Biomedical Research. This new patent builds upon the "method of use" patent issued earlier this month (US 6,335,183) by granting exclusivity for the compositions comprising heat shock fusion proteins, as well as the DNA encoding for such fusion proteins, and methods for manufacturing fusion proteins.
The patent contains broad claims that cover fusion proteins comprised of a heat shock protein fused to any antigen. Further, there are specific claims to fusion proteins comprised of heat shock proteins fused to viral, cancer or HIV antigens.
"We are excited to announce the expansion of our U.S. patent estate," said Daniel L. Korpolinski, President and Chief Executive Officer of Stressgen Biotechnologies Corporation. "This new composition of matter patent, coupled with our previously announced method of use patent, firmly solidifies our position in the field of heat shock protein fusions. The pre-GATT 17-year exclusivity of this patent should help ensure that our technology for developing multiple heat shock protein fusions will remain proprietary to 2019. We believe our patent estate will continue to expand in 2002. Our growing intellectual property portfolio, combined with the strong, positive data coming from our clinical trials, contributes two important ingredients necessary for the successful launch of HspE7, our lead fusion product candidate."
Press Release
SOURCE: Stressgen Biotechnologies Corp.
New U.S. composition patent firmly solidifies Stressgen`s position in heat shock protein fusion technology
Stressgen Broadens Heat Shock Protein Patent Estate With Issuance of Second U.S. Patent
SAN DIEGO, CA, Jan. 15 /CNW/ - Stressgen Biotechnologies Corporation (TSE:SSB - news) announced today that the U.S. Patent and Trademark Office has issued Patent Number 6,338,952, for which the Company has an exclusive worldwide license from the Whitehead Institute for Biomedical Research. This new patent builds upon the "method of use" patent issued earlier this month (US 6,335,183) by granting exclusivity for the compositions comprising heat shock fusion proteins, as well as the DNA encoding for such fusion proteins, and methods for manufacturing fusion proteins.
The patent contains broad claims that cover fusion proteins comprised of a heat shock protein fused to any antigen. Further, there are specific claims to fusion proteins comprised of heat shock proteins fused to viral, cancer or HIV antigens.
"We are excited to announce the expansion of our U.S. patent estate," said Daniel L. Korpolinski, President and Chief Executive Officer of Stressgen Biotechnologies Corporation. "This new composition of matter patent, coupled with our previously announced method of use patent, firmly solidifies our position in the field of heat shock protein fusions. The pre-GATT 17-year exclusivity of this patent should help ensure that our technology for developing multiple heat shock protein fusions will remain proprietary to 2019. We believe our patent estate will continue to expand in 2002. Our growing intellectual property portfolio, combined with the strong, positive data coming from our clinical trials, contributes two important ingredients necessary for the successful launch of HspE7, our lead fusion product candidate."
@ s.Raab
es ist ja ganz schön blauäugig,zu sagen stresgen ist im abwärtssog von imclone.vieleicht gibt es ein paar zocker,die wegen ihrer unwissenheit ihre bios auf den markt werfen,weil irgend ein wert grad zerbröselt.aber ich denke die Langfristigen Anleger schauen auf die Fakten:
Imclones Aktionären wurde ein jahr lang die Tatsachen verschwiegen,das sich der kurs prächtig entwickelt und der Ceo noch schnell seine Aktien für über 50 mill Dollar verkaufen wird.Und diese tatsachen sind jetzt rausgekommen.Ist doch klar,das bei einer kapitalisierung von 4 milliarden und keinen zugelassenem product,die lemminge langsam aufwachen und kalte füße kriegen.
zu stressgen: letztes Jahr wars noch fraglich,ob stressgen das patent bekommt oder die konkurenz.Stressgen ist ja nicht die einzige Firma, die mit Heat Shock experimentiert.
Jetzt hat Stressgen freie Bahn für die nächsten 17 Jahre!!!
Das ist DIE news,die wir hören wollen.Warum sollte gerade jetzt jemand Stressgen verkaufen?? wegen Imclone ??
Wer das macht,der hat keine Ahnung von seiner Aktie.
übrigens:stressgen mit 4 Milliarden kapitalisierung=ung. 57 Euro
es ist ja ganz schön blauäugig,zu sagen stresgen ist im abwärtssog von imclone.vieleicht gibt es ein paar zocker,die wegen ihrer unwissenheit ihre bios auf den markt werfen,weil irgend ein wert grad zerbröselt.aber ich denke die Langfristigen Anleger schauen auf die Fakten:
Imclones Aktionären wurde ein jahr lang die Tatsachen verschwiegen,das sich der kurs prächtig entwickelt und der Ceo noch schnell seine Aktien für über 50 mill Dollar verkaufen wird.Und diese tatsachen sind jetzt rausgekommen.Ist doch klar,das bei einer kapitalisierung von 4 milliarden und keinen zugelassenem product,die lemminge langsam aufwachen und kalte füße kriegen.
zu stressgen: letztes Jahr wars noch fraglich,ob stressgen das patent bekommt oder die konkurenz.Stressgen ist ja nicht die einzige Firma, die mit Heat Shock experimentiert.
Jetzt hat Stressgen freie Bahn für die nächsten 17 Jahre!!!
Das ist DIE news,die wir hören wollen.Warum sollte gerade jetzt jemand Stressgen verkaufen?? wegen Imclone ??
Wer das macht,der hat keine Ahnung von seiner Aktie.
übrigens:stressgen mit 4 Milliarden kapitalisierung=ung. 57 Euro
gemäß www.tse.com (Website Toronto Stock exchange) hat stressgen eine marktkap. von umgerechnet 223.485.877 Euro
Friday February 8, 7:59 am Eastern Time
Press Release
SOURCE: Stressgen Biotechnologies Corp.
Stressgen validates decision to aggressively pursue genital warts market
Recent Clinical Advisory Board Findings, Commercial Market Analysis, and Clinical Data Confirm Stressgen`s Decision to Focus Resources on the Treatment of Genital Warts
SAN DIEGO, CA, Feb. 8 /CNW/ - Stressgen Biotechnologies Corporation (SSB:TO) announced today that advice obtained in January from an independent Clinical Advisory Board, coupled with new market research, validates the Company`s decision that genital warts will be the first major market it will enter with HspE7. The genital warts marketplace includes many diseases caused primarily by HPV types 6 and 11 including internal and external genital warts, complex and treatment-refractory genital warts and recurrent respiratory papillomatosis (RRP). RRP, which is essentially genital warts of the upper airways, is a serious disease that at times results in considerable morbidity. Stressgen has received orphan drug designation for RRP from the Food and Drug Administration (FDA) and has initiated a Phase II clinical trial in children.
"The independent evaluation of our preclinical and clinical data by these scientific and medical HPV experts, combined with our genital warts market research, confirms the Company`s decision to pursue genital warts as our first major market for HspE7," said Daniel L. Korpolinski, President and Chief Executive Officer of Stressgen. "The clinical data released to-date demonstrate the durable efficacy of HspE7 over a broad spectrum of HPV types and diseases. The Company plans to expand labeling into other indications for HspE7 as resources become available."
In January, Stressgen assembled a Clinical Advisory Board comprised of key thought leaders with scientific and medical expertise in a wide variety of HPV-associated diseases to evaluate the Company`s clinical and commercialization strategy for HspE7. Stressgen also commissioned an independent research study to assess and map the unmet clinical needs in the management of genital warts.
After reviewing the data from Stressgen`s Phase II clinical trials in genital warts and anogenital dysplasias, as well as the first phase of the market research data, feedback from the Clinical Advisory Board confirmed the Company`s decision that genital warts will be the first major market HspE7 will enter. Further, the Board indicated that the analysis of HspE7 data suggests that a therapeutic vaccine, which induces cell-mediated immunity, can be used to potentially treat a wide variety of chronic viral infections.
The Company will briefly outline the objectives of the Clinical Advisory
Board meeting and its market research study, and discuss its 2001 fourth
quarter and year-end financial results, during its scheduled conference
call on Tuesday, February 12, 2002 at 4:00 p.m. ET (1:00 p.m. PT).
Press Release
SOURCE: Stressgen Biotechnologies Corp.
Stressgen validates decision to aggressively pursue genital warts market
Recent Clinical Advisory Board Findings, Commercial Market Analysis, and Clinical Data Confirm Stressgen`s Decision to Focus Resources on the Treatment of Genital Warts
SAN DIEGO, CA, Feb. 8 /CNW/ - Stressgen Biotechnologies Corporation (SSB:TO) announced today that advice obtained in January from an independent Clinical Advisory Board, coupled with new market research, validates the Company`s decision that genital warts will be the first major market it will enter with HspE7. The genital warts marketplace includes many diseases caused primarily by HPV types 6 and 11 including internal and external genital warts, complex and treatment-refractory genital warts and recurrent respiratory papillomatosis (RRP). RRP, which is essentially genital warts of the upper airways, is a serious disease that at times results in considerable morbidity. Stressgen has received orphan drug designation for RRP from the Food and Drug Administration (FDA) and has initiated a Phase II clinical trial in children.
"The independent evaluation of our preclinical and clinical data by these scientific and medical HPV experts, combined with our genital warts market research, confirms the Company`s decision to pursue genital warts as our first major market for HspE7," said Daniel L. Korpolinski, President and Chief Executive Officer of Stressgen. "The clinical data released to-date demonstrate the durable efficacy of HspE7 over a broad spectrum of HPV types and diseases. The Company plans to expand labeling into other indications for HspE7 as resources become available."
In January, Stressgen assembled a Clinical Advisory Board comprised of key thought leaders with scientific and medical expertise in a wide variety of HPV-associated diseases to evaluate the Company`s clinical and commercialization strategy for HspE7. Stressgen also commissioned an independent research study to assess and map the unmet clinical needs in the management of genital warts.
After reviewing the data from Stressgen`s Phase II clinical trials in genital warts and anogenital dysplasias, as well as the first phase of the market research data, feedback from the Clinical Advisory Board confirmed the Company`s decision that genital warts will be the first major market HspE7 will enter. Further, the Board indicated that the analysis of HspE7 data suggests that a therapeutic vaccine, which induces cell-mediated immunity, can be used to potentially treat a wide variety of chronic viral infections.
The Company will briefly outline the objectives of the Clinical Advisory
Board meeting and its market research study, and discuss its 2001 fourth
quarter and year-end financial results, during its scheduled conference
call on Tuesday, February 12, 2002 at 4:00 p.m. ET (1:00 p.m. PT).
wow - der impact dieser meldung ist ja gewaltig............................
hört sich doch ein bischen so an, als wollen die sich selber mut zusprechen.
krasse 1,1 mio handelsvolumen in usa/tse
kurs sinkt seit tagen. hoffe da schwebt nichts dunkles über uns..
kurs sinkt seit tagen. hoffe da schwebt nichts dunkles über uns..
wüßte auch gern mehr ?
krasses volumen für 1ne stunde handel. ob was kommt?
falls noch jemand von euch dabei ist, heute gehts wieder aufwärts!
Sunday June 24, 1:30 am Eastern Time
Press Release
SOURCE: StressGen Biotechnologies Corp.; Roche
Stressgen Biotechnologies and Roche announce global development and marketing collaboration valued up to $204 million U.S.
HspE7 is the Lead Novel Fusion Product in Stressgen`s Immunotherapeutic Pipeline for the Treatment of Human Papillomavirus (HPV)
VICTORIA, BC, Canada and SAN DIEGO, CA, USA, June 24 /CNW/ - Stressgen Biotechnologies Corporation (TSX:SSB - News) and Roche announced today that they have entered into a Collaboration Agreement for the co-development and global commercialization of Stressgen`s innovative proprietary heat shock protein (Hsp) fusion product candidate. HspE7 is in clinical development for a broad range of human papillomavirus (HPV)-related diseases including cervical and anal dysplasia, precursors to cervical and anal cancer, genital warts and recurrent respiratory papillomatosis (RRP), essentially genital warts of the upper airways, for which the Company has received orphan drug designation. All amounts, unless specified otherwise, are in U.S. dollars.
Under the terms of the agreement with Stressgen, Roche will have the worldwide exclusive right to market and sell the HspE7 product and Stressgen will have the right to co-promote the product in the U.S. to certain physician specialties. In addition to an equity investment of $5 million, Roche will pay Stressgen upfront fee and milestone payments, totaling up to $200 million if all development and commercial milestones are achieved, and sales-based payments.
"Roche has a long tradition in successfully developing and commercializing anti-viral drugs, alone or in partnership with other companies. Through this agreement, we will strengthen our leadership in this important therapeutic area, and we are looking forward to, together with Stressgen, developing a promising drug which will bring a major treatment advance to patients suffering from HPV," said William M. Burns, Head of Roche`s Pharmaceuticals Division.
"We are delighted to partner with Roche, a company that has established a clear leadership position in the diagnosis and treatment of HPV, as well as other serious and chronic viral diseases," said Daniel L. Korpolinski, President and Chief Executive Officer of Stressgen. "This alliance with Roche validates Stressgen`s achievements to date in the clinic with HspE7, and provides us with an outstanding commercial partner for potential marketing of the first Hsp fusion product for HPV. We expect to build on the success of HspE7, and increase our technology pipeline by developing additional Hsp fusion candidates in the areas of hepatitis B, herpes simplex and HIV viruses."
Further financial terms were not disclosed. A joint decision-making governance structure has been established with equal representation from both organizations to oversee and guide the future development of HspE7. The terms of the collaboration agreement are subject to the United States Federal Trade Commission (FTC) approval.
HspE7 is in Phase II and Phase III clinical trials for RRP and anal dysplasia. The total market for genital warts, RRP, anal dysplasia and cervical dysplasia represents over one million new patients a year in the U.S. Applying the same proprietary heat shock protein fusion technology that led to the discovery of HspE7, the Company is also advancing a pipeline of novel immunotherapeutics for other serious and chronic viral diseases.
About HPV
HPV infection is one of the most prevalent sexually transmitted diseases, and it is estimated that there are approximately 5.5 million new cases of genital HPV infections each year in the U.S. alone. HPV infection can also cause recurrent respiratory papillomatosis, a wart infection of the upper airways, and cervical and anal dysplasias, potentially leading to development of cancer.
Sunday June 24, 1:30 am Eastern Time
Press Release
SOURCE: StressGen Biotechnologies Corp.; Roche
Stressgen Biotechnologies and Roche announce global development and marketing collaboration valued up to $204 million U.S.
HspE7 is the Lead Novel Fusion Product in Stressgen`s Immunotherapeutic Pipeline for the Treatment of Human Papillomavirus (HPV)
VICTORIA, BC, Canada and SAN DIEGO, CA, USA, June 24 /CNW/ - Stressgen Biotechnologies Corporation (TSX:SSB - News) and Roche announced today that they have entered into a Collaboration Agreement for the co-development and global commercialization of Stressgen`s innovative proprietary heat shock protein (Hsp) fusion product candidate. HspE7 is in clinical development for a broad range of human papillomavirus (HPV)-related diseases including cervical and anal dysplasia, precursors to cervical and anal cancer, genital warts and recurrent respiratory papillomatosis (RRP), essentially genital warts of the upper airways, for which the Company has received orphan drug designation. All amounts, unless specified otherwise, are in U.S. dollars.
Under the terms of the agreement with Stressgen, Roche will have the worldwide exclusive right to market and sell the HspE7 product and Stressgen will have the right to co-promote the product in the U.S. to certain physician specialties. In addition to an equity investment of $5 million, Roche will pay Stressgen upfront fee and milestone payments, totaling up to $200 million if all development and commercial milestones are achieved, and sales-based payments.
"Roche has a long tradition in successfully developing and commercializing anti-viral drugs, alone or in partnership with other companies. Through this agreement, we will strengthen our leadership in this important therapeutic area, and we are looking forward to, together with Stressgen, developing a promising drug which will bring a major treatment advance to patients suffering from HPV," said William M. Burns, Head of Roche`s Pharmaceuticals Division.
"We are delighted to partner with Roche, a company that has established a clear leadership position in the diagnosis and treatment of HPV, as well as other serious and chronic viral diseases," said Daniel L. Korpolinski, President and Chief Executive Officer of Stressgen. "This alliance with Roche validates Stressgen`s achievements to date in the clinic with HspE7, and provides us with an outstanding commercial partner for potential marketing of the first Hsp fusion product for HPV. We expect to build on the success of HspE7, and increase our technology pipeline by developing additional Hsp fusion candidates in the areas of hepatitis B, herpes simplex and HIV viruses."
Further financial terms were not disclosed. A joint decision-making governance structure has been established with equal representation from both organizations to oversee and guide the future development of HspE7. The terms of the collaboration agreement are subject to the United States Federal Trade Commission (FTC) approval.
HspE7 is in Phase II and Phase III clinical trials for RRP and anal dysplasia. The total market for genital warts, RRP, anal dysplasia and cervical dysplasia represents over one million new patients a year in the U.S. Applying the same proprietary heat shock protein fusion technology that led to the discovery of HspE7, the Company is also advancing a pipeline of novel immunotherapeutics for other serious and chronic viral diseases.
About HPV
HPV infection is one of the most prevalent sexually transmitted diseases, and it is estimated that there are approximately 5.5 million new cases of genital HPV infections each year in the U.S. alone. HPV infection can also cause recurrent respiratory papillomatosis, a wart infection of the upper airways, and cervical and anal dysplasias, potentially leading to development of cancer.
wow, die meldung ist eingeschlagen wie ne bombe. klasse, der kurs ist schlechter als vor dem deal über 204 Mio US Dollar. Wenn man mal den einfluss des extrem schlechten marktumfeldes abzieht, bleibt dennoch ein meines erachtens unerklärlicher verfall. biotech ist mega out. stressgen ist mit 219 Mio Can-Dollar bewertet (umrechnung www.oanda.com, hab grad keine zeit mehr...), der deal über 204 Mio hat nix gebracht. klasse. wurde nur genutzt um auszusteigen. naja, viel erfolg noch allen, die investiert sind.
news
Thursday August 8, 7:59 am Eastern Time
Press Release
SOURCE: StressGen Biotechnologies Corp.
Stressgen announces completion of enrollment in Phase II clinical trial of HspE7 for recurrent respiratory papillomatosis in children
Orphan Drug Status for RRP May Provide Fastest Route to Market
VICTORIA, BC and SAN DIEGO, CA, Aug. 8 /PRNewswire-FirstCall/ - Stressgen Biotechnologies Corporation (TSX:SSB - News) announced today that it has completed enrollment in its Phase II clinical trial of HspE7 for pediatric patients suffering from a human papillomavirus (HPV)-related disease called recurrent respiratory papillomatosis (RRP), essentially warts of the upper airways. According to a survey published in 1995, there were approximately 6,000 active cases and 2,300 new cases of RRP diagnosed annually. ADVERTISEMENT
Conducted at multiple clinical sites in the U.S., the trial involves 27 pediatric patients that currently require frequent surgery to manage their disease. Patients are receiving 500 mcg doses of HspE7 administered three times at monthly intervals. The endpoint for this trial is to achieve an increased interval between clinically required surgeries. Data from this study could be available as early as this year.
The Company was granted orphan drug status for HspE7 for the RRP indication from the U.S. Food and Drug Administration (FDA) in March of 2001. HspE7, a novel immunotherapeutic, developed with Stressgen`s proprietary heat shock protein fusion technology, CoVal(TM) fusions, was developed to invoke a potent immune response to HPV. Stressgen, in collaboration with Roche, is developing HspE7 for a broad range of HPV-related diseases.
"The papillomas in RRP almost always recur," said John R. Neefe, M.D., Senior Vice President of Clinical Research for Stressgen Biotechnologies. "Frequent recurrence leads to repeated painful surgical procedures, sometimes hundreds of procedures over a lifetime. This pattern of disease is deeply frustrating to affected children, their families, and to the medical professionals who treated them."
"HspE7 could become effective medical therapy for RRP," added Dr. Neefe. "By reducing or preventing recurrence, HspE7 could break the unhappy cycle of repeated surgeries. Genital warts, caused by the same types of HPV as RRP, also have a pattern of frequent recurrences, which fail to respond to available therapies. Stressgen`s clinical data have already suggested that HspE7 can break the recurrence pattern in genital warts."
"This is yet another significant clinical milestone for Stressgen, and marks important, ongoing progress for our lead compound, HspE7, for the potential treatment of a broad range of HPV-related conditions," said Daniel L. Korpolinski, President and Chief Executive Officer of Stressgen. "Physicians need a new treatment option that can address the recurrence associated with HPV-related diseases. We are hopeful that HspE7, with its orphan drug designation for RRP, could be the first drug available to treat the symptoms associated with this tragic disease and potentially manage or even prevent recurrence. Ultimately, HspE7 may be demonstrated to improve the quality of life for children suffering from this dreadful condition. We remain on track with our timelines for filing a biologics license application (BLA) for marketing approval for RRP with the FDA."
About Stressgen Biotechnologies Corporation
Stressgen, a biopharmaceutical company, focuses on the discovery, development and commercialization of innovative CoVal(TM) (see below) fusion immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. In addition to developing HspE7 for diseases caused by human papillomavirus ("HPV"), the Company has a program to evaluate CoVal(TM) fusions in hepatitis B and has initiated research studies to evaluate its CoVal(TM) fusion technology in the treatment of hepatitis C, herpes simplex and HIV. Stressgen is also an internationally recognized supplier of research products used by scientists worldwide for the study of cellular stress, apoptosis, oxidative stress and neurobiology.
In June 2002, Stressgen announced a Collaboration Agreement with Roche for the co-development and global commercialization of HspE7, Stressgen`s lead product candidate for HPV-related diseases. HPV is one of the most common sexually transmitted diseases, estimated to infect over 50 percent of the sexually active population. There are 5.5 million new cases of genital HPV infection diagnosed per year in the U.S. alone, including over one million cases of genital warts. In addition to genital warts and recurrent respiratory papillomatosis, HPV infection can cause cervical cancer and a variety of precancerous conditions, including anal and cervical dysplasia.
The Company is a member of the S&P/TSX Composite Index and is publicly traded on the TSX Toronto Stock Exchange under the symbol SSB.
About CoVal(TM) Fusions
Stressgen capitalizes upon the immunostimulatory powers of heat shock proteins utilizing recombinant technology to fuse, or covalently link, a stress protein with a protein antigen to create a single hybrid protein designed to trigger the immune system to recognize that antigen. For more information about our CoVal(TM) fusion technology, or Stressgen, please visit us at our website located at www.stressgen.com.
This news release contains forward-looking statements that involve risks and uncertainties, including statements regarding the release of data from clinical trials and expected uses of immunotherapeutics. Factors that may cause the ultimate results to be materially different from those implied by such statements include risks of delays in conducting clinical trials and differences between the results of preliminary research and clinical trials. Please refer to our periodic reports filed with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission for a more comprehensive discussion of these and other risks.
Stressgen Contacts:
Donna Slade Jennifer Matterson
Director, Investor Relations Communications Coordinator
10241 Wateridge Circle, Ste. C200 350-4243 Glanford Avenue
San Diego, CA USA 92121 Victoria, BC CANADA V8Z 4B9
Tel: 858/202-4900 Tel: 250/744-2811
Dir: 858/202-4945 Fax: 250/744-3331
Fax: 858/450-6849 jmatterson@stressgen.com
dslade@stressgen.com
SOURCE: StressGen Biotechnologies Corp.
Thursday August 8, 7:59 am Eastern Time
Press Release
SOURCE: StressGen Biotechnologies Corp.
Stressgen announces completion of enrollment in Phase II clinical trial of HspE7 for recurrent respiratory papillomatosis in children
Orphan Drug Status for RRP May Provide Fastest Route to Market
VICTORIA, BC and SAN DIEGO, CA, Aug. 8 /PRNewswire-FirstCall/ - Stressgen Biotechnologies Corporation (TSX:SSB - News) announced today that it has completed enrollment in its Phase II clinical trial of HspE7 for pediatric patients suffering from a human papillomavirus (HPV)-related disease called recurrent respiratory papillomatosis (RRP), essentially warts of the upper airways. According to a survey published in 1995, there were approximately 6,000 active cases and 2,300 new cases of RRP diagnosed annually. ADVERTISEMENT
Conducted at multiple clinical sites in the U.S., the trial involves 27 pediatric patients that currently require frequent surgery to manage their disease. Patients are receiving 500 mcg doses of HspE7 administered three times at monthly intervals. The endpoint for this trial is to achieve an increased interval between clinically required surgeries. Data from this study could be available as early as this year.
The Company was granted orphan drug status for HspE7 for the RRP indication from the U.S. Food and Drug Administration (FDA) in March of 2001. HspE7, a novel immunotherapeutic, developed with Stressgen`s proprietary heat shock protein fusion technology, CoVal(TM) fusions, was developed to invoke a potent immune response to HPV. Stressgen, in collaboration with Roche, is developing HspE7 for a broad range of HPV-related diseases.
"The papillomas in RRP almost always recur," said John R. Neefe, M.D., Senior Vice President of Clinical Research for Stressgen Biotechnologies. "Frequent recurrence leads to repeated painful surgical procedures, sometimes hundreds of procedures over a lifetime. This pattern of disease is deeply frustrating to affected children, their families, and to the medical professionals who treated them."
"HspE7 could become effective medical therapy for RRP," added Dr. Neefe. "By reducing or preventing recurrence, HspE7 could break the unhappy cycle of repeated surgeries. Genital warts, caused by the same types of HPV as RRP, also have a pattern of frequent recurrences, which fail to respond to available therapies. Stressgen`s clinical data have already suggested that HspE7 can break the recurrence pattern in genital warts."
"This is yet another significant clinical milestone for Stressgen, and marks important, ongoing progress for our lead compound, HspE7, for the potential treatment of a broad range of HPV-related conditions," said Daniel L. Korpolinski, President and Chief Executive Officer of Stressgen. "Physicians need a new treatment option that can address the recurrence associated with HPV-related diseases. We are hopeful that HspE7, with its orphan drug designation for RRP, could be the first drug available to treat the symptoms associated with this tragic disease and potentially manage or even prevent recurrence. Ultimately, HspE7 may be demonstrated to improve the quality of life for children suffering from this dreadful condition. We remain on track with our timelines for filing a biologics license application (BLA) for marketing approval for RRP with the FDA."
About Stressgen Biotechnologies Corporation
Stressgen, a biopharmaceutical company, focuses on the discovery, development and commercialization of innovative CoVal(TM) (see below) fusion immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. In addition to developing HspE7 for diseases caused by human papillomavirus ("HPV"), the Company has a program to evaluate CoVal(TM) fusions in hepatitis B and has initiated research studies to evaluate its CoVal(TM) fusion technology in the treatment of hepatitis C, herpes simplex and HIV. Stressgen is also an internationally recognized supplier of research products used by scientists worldwide for the study of cellular stress, apoptosis, oxidative stress and neurobiology.
In June 2002, Stressgen announced a Collaboration Agreement with Roche for the co-development and global commercialization of HspE7, Stressgen`s lead product candidate for HPV-related diseases. HPV is one of the most common sexually transmitted diseases, estimated to infect over 50 percent of the sexually active population. There are 5.5 million new cases of genital HPV infection diagnosed per year in the U.S. alone, including over one million cases of genital warts. In addition to genital warts and recurrent respiratory papillomatosis, HPV infection can cause cervical cancer and a variety of precancerous conditions, including anal and cervical dysplasia.
The Company is a member of the S&P/TSX Composite Index and is publicly traded on the TSX Toronto Stock Exchange under the symbol SSB.
About CoVal(TM) Fusions
Stressgen capitalizes upon the immunostimulatory powers of heat shock proteins utilizing recombinant technology to fuse, or covalently link, a stress protein with a protein antigen to create a single hybrid protein designed to trigger the immune system to recognize that antigen. For more information about our CoVal(TM) fusion technology, or Stressgen, please visit us at our website located at www.stressgen.com.
This news release contains forward-looking statements that involve risks and uncertainties, including statements regarding the release of data from clinical trials and expected uses of immunotherapeutics. Factors that may cause the ultimate results to be materially different from those implied by such statements include risks of delays in conducting clinical trials and differences between the results of preliminary research and clinical trials. Please refer to our periodic reports filed with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission for a more comprehensive discussion of these and other risks.
Stressgen Contacts:
Donna Slade Jennifer Matterson
Director, Investor Relations Communications Coordinator
10241 Wateridge Circle, Ste. C200 350-4243 Glanford Avenue
San Diego, CA USA 92121 Victoria, BC CANADA V8Z 4B9
Tel: 858/202-4900 Tel: 250/744-2811
Dir: 858/202-4945 Fax: 250/744-3331
Fax: 858/450-6849 jmatterson@stressgen.com
dslade@stressgen.com
SOURCE: StressGen Biotechnologies Corp.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,31 | |
| 0,00 | |
| -0,18 | |
| -0,19 | |
| +0,60 | |
| +0,56 | |
| +0,07 | |
| -0,08 | |
| +0,12 | |
| +0,40 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 134 | ||
| 82 | ||
| 49 | ||
| 33 | ||
| 28 | ||
| 27 | ||
| 26 | ||
| 14 | ||
| 13 | ||
| 11 |
